Affivant Sciences GmbH

While most immuno-oncology (IO) approaches are based on activation of cytotoxic T-cells, Affivant Sciences develops novel bispecific tetravalent monoclonal antibodies which engage cells from the innate immune system (Natural Killer cells, macrophages) referred to as Innate Cell Engagers (ICEs). This overcomes safety limitations of T cell engagers, and is expected to drive responses in T cell deficient tumor types. Affivant's lead asset, AFVT-2101, binds to Folate Receptor alpha, a tumor target that has been clinically validated for ovarian cancer. The ultra high affinity, selective, CD16A engagement of AFVT-2101 overcomes limitations of Fc active, or Fc enhanced antibodies. We are seeking to grow our pipeline with novel assets that offer high potential in combination with AFVT-2101.